Related Experiment Video
Updated: Mar 15, 2026
10:29
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
2.6K
A Triazinone Derivative Inhibits HIV-1 Replication by Interfering with Reverse Transcriptase Activity.
Emiko Urano1,2, Kosuke Miyauchi1,3, Yoko Kojima4
1AIDS Research Center, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo, 162-8640, Japan.
Chemmedchem
|September 17, 2016
Summary
A novel HIV-1 inhibitor, compound 1, effectively suppresses viral replication and inhibits HIV-1 reverse transcriptase. It shows a unique resistance profile against common mutations, offering a new therapeutic avenue.
Area of Science:
- Virology
- Medicinal Chemistry
- Drug Discovery
Background:
- Human Immunodeficiency Virus type 1 (HIV-1) replication is a complex process.
- Reverse transcriptase (RT) is a critical enzyme in HIV-1 replication and a target for antiviral drugs.
- Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are a key class of HIV-1 therapeutics.
Purpose of the Study:
- To identify and characterize novel inhibitors of HIV-1 replication.
- To evaluate the efficacy and resistance profile of a newly identified compound, 6-(tert-butyl)-4-phenyl-4-(trifluoromethyl)-1H,3H-1,3,5-triazin-2-one (compound 1).
Main Methods:
- Compound library screening for HIV-1 replication inhibition.
- In vitro antiviral assays to determine EC50 values against clinical isolates.
- In vitro assays to assess inhibition of HIV-1 reverse transcriptase activity.
- Resistance selection assays to identify mutations conferring resistance.
- Computer-assisted docking simulations to predict binding interactions.
Main Results:
- Compound 1 demonstrated potent inhibition of HIV-1 replication with EC50 values ranging from 107.9 to 145.4 nm against primary isolates.
- Compound 1 inhibited HIV-1 RT activity with an EC50 of 4.3 microm.
- A resistant HIV-1 variant with an RT L100I mutation showed a 41-fold increase in resistance to compound 1.
- Compound 1 remained effective against HIV-1 with the RT K103N mutation.
- Docking simulations suggested compound 1 binds to the NNRTI binding pocket similarly to efavirenz but with a distinct positioning relative to RT K103.
Conclusions:
- Compound 1 is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI).
- It possesses a unique drug-resistance profile, potentially overcoming existing resistance mechanisms.
- Further investigation of compound 1 is warranted for its therapeutic potential against HIV-1.
Related Concept Videos
01:10Retrovirus Life Cycles
50.2K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.2K
01:29Viruses with RNA Genomes
1.2K
RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
1.2K
01:52Eukaryotic Transcription Inhibitors
11.2K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.2K